Triple therapy using telaprevir or boceprevir combined plus pegylated interferon and ribavirin improved outcomes in about 40% of patients with advanced hepatitis C, even if the cases involved cirrhosis or a history of failed therapy, French researchers reported at the European Association for the Study of the Liver meeting. Researchers said the benefits of the treatment must be weighed against the substantial risk of adverse effects.

Related Summaries